Drugs / recombinant HCG
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT01507376 | Oct 2010 → Sep 2012 | — | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT00954265 | Aug 2005 → Dec 2007 | Somatomedin, embryonic, perifoveal exudative vascular anomalous complex, pregnancy disorder | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00953628 | Aug 2005 → Dec 2006 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant HCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00954265 ↗ |
| Known as | Ovitrelle | “Group A consisted of 60 women who received recombinant hCG(250 µg Ovitrelle)” NCT01507376 ↗ |
| Modality | Protein / enzyme biologic | “250 mcg recombinant HCG” NCT00954265 ↗ |